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Anti-Jo-l is the most frequently identified autoantibody in 
the idiopathic inflammatory myopathies (11M) and patients 
with Jo-l may also develop interstitial pneumonitis, arthritis, 
and "mechanic's hands", Anti-signal recognition particle 
(SRP) identifies a second subgroup of IIM with severe muscle 
weakness, Patients with either antibody have a worse 
outlook.' We assessed the effectiveness of tacrolimus in 
treating such patients. 
Patients were eligible if they had muscle weakness, raised 
serum creatine kinase (CK), electromyographic and biopsy 
evidence of active disease, and if treatment with prednisone 
and at least one other concomitantly adminstered 
immunosuppressive agent had failed. Patients received oral 
tacrolimus (0'075 mg/kg daily) in twice daily doses to achieve 
a 12-h plasma trough concentration of 5-20 ng/mL. Their 
manual muscle strength, serum CK, functional status as 
determined by the disabiliry index (DI) of the Health 
Assessment Questionnaire (HAQ), and daily prednisone dose 
were recorded as outcome measures. Eight patients (five 
women, age range 30-70 years), were treated. Time from 
disease onset to treatment with tacrolimus ranged from 
9 months to almost 9 years. Six had anti-Jo-l and two 
had anti-SRP autoantibodies. All had corticosteroid and 
methotrexate-resistant disease; four had failed azathioprine, 
two cyclophosphamide, one intravenous immune globulin, 
and one plasmapheresis. 
All patients had improved muscle strength after tacrolimus 
and five ofthe six anti-Jo-l patients regained normal strength 
(three within 3 months, two within 6 months). Mean CK of 
the six anti-Jo-l patients decreased from 3114 IU/mL to 87 
IU/mL (p<O'Ol) and three returned to normal within 1 
month. The two anti-SRP patients had a decrease in their 
serum CK and strength improved. Patients with the anti-Jo-l 
antibody had an improved functional status (mean DI of the 
HAQ 0·98 to 0'48, p<0·005). Mean daily prednisone dose 
decreased by 80% in the six anti-Jo-l-positive patients (25 
mg to 5 mg, p<0'005, and one patient is off prednisone). 
Patients have received 368 patient months of tacrolimus 
treatment (range, 17-74 months; mean, 46 months) and 
none have had a flare-up of myositis flare when their 
tacrolimus serum concentrations were within the therapeutic 
range. Suboptimum concentrations (one patient) and drug 
discontinuation (two patients, figure), led to flares that 
responded favourably to restarting tacrolimus. Extramuscular 
manifestations such as fever', polyarthritis, and "mechanics 
hands" improved with tacrolimus. Five of the six Jo-l-
positive patients had radiographic evidence of diffuse 
parenchymal interstitial infiltrates and two required treatment 
with oxygen. One had stable pulmonary function tests, one 
worsened slightly, and three responded favourably. The mean 
improvement in the forced vital capacity after 12, 21, and 
37 months of tacrolimus in these three patients was 0·62 L 
(a 22% increase). Carbon monoxide diffusion improved 
in two patients and total lung capacity increased an average 
of 15%. 
Tacrolimus was well tolerated. The serum creatinine 
increased in all patients but dosage modification led to 
improvement in all but one patient who developed 
accelerated hypertension and worsening renal function with a 
creatinine of 4·1 mg/dL. Tacrolimus was stopped and muscle 
strength and serum CK remain normal 12 months later. Two 
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patients developed mild anaemia and hypertension and one 
experienced gynaecomastia which resolved. No patients had 
an opportunistic infection. Another SRP-positive patient 
stopped tacrolimus due to concerns over side-effects. 
Only 9% (3/34) of previously reported antisynthetase 
antibody-positive patients responded completely to 
treatment. 2 Our six J o-I-positive patients had a good response 
to tacrolimus and in five it was sustained. Despite a mean 
tacrolimus treatment duration of 46 months and decreasing 
corticosteroid doses, no patient flared during treatment. 
There were three disease exacerbations when tacrolimus was 
tapered or discontinued. The prevalence of interstitial lung 
disease is increased in myositis patients with antisynthetase 
autoantibodies, is associated with reduced survival, and was 
the immediate cause of mortality in 58% of all deaths related 
to 11M.' Four of our five Jo-I-positive patients with interstitial 
lung disease are stable or have improved, 
Tacrolimus has been effective in treating pyoderma 
gangrenosum, psoriasis, uveitis, Beh!;ets disease, nephrotic 
syndrome, and primary sclerosing cholangitis.' It inhibits 
activation of CD4+ T helper cells through several calcium-
associated events involved in lymphokine gene transcription 
and interleukin-2 and other cytokines are also inhibitied.' 
Because polymyositis is predominantly aT-cell-mediated 
disease, one might expect IIM patients to respond more 
favourably to tacrolimus than those with dermatomyositis 
(a B-cell mediated disease). We suggest that tacrolimus be 
considered and studied in the treatment of patients with 
severe myositis with poor prognostic autoantibodies; and 
patients with immunological (T-cell mediated) interstitial 
lung disease before they develop pulmonary fibrosis. 
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